Not all sufferers with CLL involve therapy. Even with all the latest developments, the iwCLL however recommends watchful observation for sufferers with asymptomatic disorder.86 This advice is based on no less than two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,